Tag: cancer | I3PT Parc Taulí

New therapy to avoid chemotherapy in lung cancer

New therapy to avoid chemotherapy in lung cancer https://www.tauli.cat/institut/wp-content/uploads/2022/07/laia-vila-quimioterapia-1200x674.jpg 1080 607 Mireia Córcoles Mireia Córcoles https://www.tauli.cat/institut/wp-content/uploads/2022/11/Tezza-0184-150x150.jpg July 25, 2022 July 26, 2022

By: Mireia Córcoles

July 25, 2022

The results of a trial, with the participation of the I3PT, demonstrate the effectiveness of a new treatment that combines two immunotherapy drugs in patients with metastatic lung cancer read more

An innovative treatment for rectal cancer improves morbidity and prevents permanent sequelae

An innovative treatment for rectal cancer improves morbidity and prevents permanent sequelae https://www.tauli.cat/institut/wp-content/uploads/2022/06/GR-X.-Serra.jpg 1024 575 Mireia Córcoles Mireia Córcoles https://www.tauli.cat/institut/wp-content/uploads/2022/11/Tezza-0184-150x150.jpg June 27, 2022 October 3, 2022

By: Mireia Córcoles

June 27, 2022

The current results of the study are very promising and pave the way for a change in surgical strategy in the treatment of these tumors, which would involve a treatment of local chemo-radiotherapy and minimal local surgery, preserving the rectum. read more

Tricin as a potential enhancer for the treatment of cisplatin-based skin cancer

Tricin as a potential enhancer for the treatment of cisplatin-based skin cancer https://www.tauli.cat/institut/wp-content/uploads/2020/06/1593154770_tmp_IMG_1783-e1593155055158.jpg 585 409 Guillem Cebrian Guillem Cebrian https://www.tauli.cat/institut/wp-content/uploads/2020/02/IMG-1030-150x150.png June 25, 2020 March 25, 2021

By: Guillem Cebrian

June 25, 2020

At the end of December 2019, we talked about the effectiveness of trichina as an adjuvant of cisplatin in treatment. Squamous cell carcinoma is the second most common type of skin cancer. It causes the abnormal growth of squamous cells in the epidermis and represents 20-25% of all skin cancers in Spain. This study led by an I3PT team, led by Sílvia Gil, in close collaboration with…

Taby Diagnostics wins the 3rd prize of the EIT Health Cross-KIC-Business Idea Competition 2018

Taby Diagnostics wins the 3rd prize of the EIT Health Cross-KIC-Business Idea Competition 2018 https://www.tauli.cat/institut/wp-content/uploads/2020/02/Final_EIT-Health_Business-Idea-Competition2018_sized-1024x659.jpg 1024 659 Xavier Gallego Xavier Gallego https://www.tauli.cat/institut/wp-content/uploads/2019/11/Xavi-150x150.jpg November 20, 2018 February 22, 2020

By: Xavier Gallego

November 20, 2018

Jointly organized by EIT Health, EIT Raw Materials, and EIT Food, the Business Idea Competition helps to improve cross-sectoral innovation performance in EIT RIS countries along the following thematic areas: 1) Food, 2) Health, and 3) Raw Materials.